Cosmetic cross-reference

Durapatite

CAS 1306-06-5

Durapatite (CAS 1306-06-5) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 1 adverse event association.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
1
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Durapatite
CAS Number
1306-06-5
UNII
91D9GV0Z28
InChIKey
XYJRXVWERLGGKC-UHFFFAOYSA-D
ChEMBL ID
CHEMBL2218916
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
HYDROXYAPATITECALCIUM HYDROXYAPATITETRIBASIC CALCIUM PHOSPHATE
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL2218916 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 15 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Regurgitation 15 44.693 10067171
Vitamin B12 deficiency 17 36.675 10047609
Periarthritis 12 32.949 10034464
Oropharyngeal discomfort 14 28.426 10068318
Dyspepsia 43 26.185 10013946
Eructation 15 26.03 10015137
Spirometry abnormal 6 19.588 10041630
Atrioventricular conduction time shortened 3 19.356 10068180
Diarrhoea 151 18.668 10012735
Mite allergy 6 17.528 10077290
Mycotic allergy 6 16.485 10052758
Dust allergy 6 16.228 10077439
Klebsiella test positive 6 15.647 10070091
Abdominal distension 35 15.453 10000060
Blood electrolytes increased 3 15.11 10061716

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
HYDROXYAPATITE 47628 SU MTHSPL
CALCIUM HYDROXYAPATITE 47628 SU MTHSPL
TRIBASIC CALCIUM PHOSPHATE 47628 SU MTHSPL
tribasic calcium phosphate 47628 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Durapatite used for in pharmaceutical contexts?

Durapatite (CAS 1306-06-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Durapatite?

Durapatite has 1 DrugCentral/FAERS adverse event association. Rendered reaction terms include Regurgitation, Vitamin B12 deficiency, Periarthritis, Oropharyngeal discomfort, Dyspepsia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Durapatite also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Hydroxyapatite with EU status "restricted".

What clinical phase is Durapatite in?

Durapatite is rendered with ChEMBL max phase 2.